A closer look at “Ketamine Medicines Surge as Trump Administration Embraces Psyelics”, exactly as the source publishes it. The market for ketamine-based medicines is accelerating as pharmaceutical companies respond to the Trump administration's open support for psychedelic therapies. Once known mainly as an anesthetic and party drug, ketamine is now at the center of a wave of drug development aimed at treating depression, PTSD, and other mental health conditions. Companies are racing to patent new delivery methods and chemical variations of the drug, from nasal sprays to slow-release pills, hoping to capture a share of a market that analysts say could reach billions of dollars.
Researchers are exploring both novel and repurposed forms of ketamine, including esketamine, which is already approved as a nasal spray for treatment-resistant depression. The administration's favorable stance has reduced regulatory uncertainty and encouraged investment in clinical trials. For the complete material, the listing points back to the source inside the network.